For the past couple of years, there has been mounting interest in the medical abilities of cannabidiol (“CBD”), a cannabinoid produced by the cannabis plant. This was compounded by the 2018 Farm Bill which legalized industrial hemp and its derivatives and pushed CBD even more into the mainstream. The cannabinoid is said to be effective against a wide range of medical conditions, ranging from certain forms of epilepsy, chronic pain, anxiety, and depression.
A growing body of research has also found that cannabidiol can help treat cocaine addiction. In a new meta-study, scientists analyzed 14 studies from the past five years on the administration of CBD in animal subjects consuming cocaine, and they determined that CBD appears to have a variety of effects that counteract addictive behaviors. The study, published this month in the journal Pharmacology Biochemistry and Behavior states that “CBD promotes reduction on cocaine self-administration. Also, it interferes with cocaine-induced brain reward stimulated and dopamine release.”
“CBD promotes alteration in contextual memory associated with cocaine and in the neuroadaptations, hepatoxicity, and seizures induced by cocaine.” Despite admitting that not all of the studies under review were consistent with each other and stressing on the need for human trials, the researchers said that animal research generally indicated that CBD can reduce self-administration of cocaine and many symptoms of addiction.
For instance, in a study from 2019, researchers reported that “the systemic administration of CBD (20mg/kg) 30 minutes before testing reduced the self-administration of a low dose of cocaine. However, lower concentrations of CBD did not produce the effect. Similarly, a study from 2018 found that a daily 20 mg/kg of CBD led to a “significant difference in the consumption of cocaine on the 10th day of the study and lower consumption throughout the entire procedure compared to the control group of mice.”
A separate study found that administering CBD to rats with a history of cocaine use made them less anxious, as evidenced by “the greater time spent in the open arms of the elevated plus-maze.”
The authors of the new meta-study concluded that “the evidence described in the present systematic review indicated that CBD is a promising adjunct therapy for the treatment of cocaine dependence due to its effect on cocaine consumption, brain reward, anxiety, related contextual memories, neuroadaptations, and hepatic protection as well as its anticonvulsant effect and safety.”
The findings of this research are likely to be welcomed by cannabis companies like Pure Extracts Corp. since the industry has always believed that scientists have barely scratched the surface of the therapeutic effects of cannabis compounds.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.